NCT01980940View on ClinicalTrials.gov

The Single Dose Pharmacokinetics of Two and Proof of Efficacy of One New Etoricoxib Gel Formulation in Participants With Osteoarthritis (MK-0663-168)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

December 23, 2013

Primary Completion Date

November 26, 2014

Study Completion Date

November 26, 2014

Conditions
Osteoarthritis Pain
Interventions
DRUG

Etoricoxib 75 mg 4% DMSO Gel

Etoricoxib 75 mg 4% DMSO gel applied topically.

DRUG

Etoricoxib 75 mg 4% PG Gel

Etoricoxib 75 4% PG gel applied topically.

DRUG

Etoricoxib 150 mg 4% DMSO Gel

Etoricoxib 150 mg 4% DMSO gel applied topically.

DRUG

Etoricoxib 150 mg 4% PG Gel

Etoricoxib 150 mg 4% PG gel applied topically.

DRUG

Etoricoxib 163 mg 4% DMSO gel

Etoricoxib 163 mg 4% DMSO gel applied topically

DRUG

Placebo

Placebo gel applied topically.

DRUG

Etoricoxib 50 mg 4% DMSO

Etoricoxib 50 mg 4% DMSO gel applied topically.

DRUG

Matching Placebo to Etoricoxib 50 mg 4% DMSO Gel

Matching Placebo to Etoricoxib 50 mg 4% DMSO gel applied topically.

All Listed Sponsors
lead

Organon and Co

INDUSTRY

NCT01980940 - The Single Dose Pharmacokinetics of Two and Proof of Efficacy of One New Etoricoxib Gel Formulation in Participants With Osteoarthritis (MK-0663-168) | Biotech Hunter | Biotech Hunter